Prudential Financial Inc. Grows Position in Collegium Pharmaceutical, Inc. (COLL)

Prudential Financial Inc. grew its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 62.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 557,050 shares of the specialty pharmaceutical company’s stock after buying an additional 214,860 shares during the period. Prudential Financial Inc. owned approximately 1.88% of Collegium Pharmaceutical worth $5,843,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in COLL. Bank of New York Mellon Corp lifted its position in shares of Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 3,775 shares during the last quarter. American International Group Inc. increased its stake in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after purchasing an additional 2,163 shares during the period. Vanguard Group Inc. increased its stake in shares of Collegium Pharmaceutical by 7.8% in the first quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock worth $8,113,000 after purchasing an additional 58,398 shares during the period. Geode Capital Management LLC increased its stake in shares of Collegium Pharmaceutical by 3.4% in the first quarter. Geode Capital Management LLC now owns 146,568 shares of the specialty pharmaceutical company’s stock worth $1,474,000 after purchasing an additional 4,866 shares during the period. Finally, UBS Group AG increased its stake in shares of Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 10,174 shares during the period. 77.23% of the stock is owned by institutional investors.

Collegium Pharmaceutical, Inc. (NASDAQ COLL) opened at $16.81 on Monday. Collegium Pharmaceutical, Inc. has a 12 month low of $7.37 and a 12 month high of $19.21.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The firm had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. During the same period in the previous year, the company posted ($1.13) earnings per share. The company’s quarterly revenue was up 2814.6% compared to the same quarter last year. analysts forecast that Collegium Pharmaceutical, Inc. will post -2.56 EPS for the current year.

COLL has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, November 17th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Monday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $14.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, September 8th. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $19.33.

In other Collegium Pharmaceutical news, CTO Alison B. Fleming sold 4,029 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $17.00, for a total transaction of $68,493.00. Following the sale, the chief technology officer now directly owns 28,513 shares of the company’s stock, valued at $484,721. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Thomas Heffernan sold 50,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total value of $776,500.00. Following the sale, the chief executive officer now directly owns 558,987 shares in the company, valued at $8,681,068.11. The disclosure for this sale can be found here. Insiders have sold 58,630 shares of company stock worth $924,360 over the last 90 days. Corporate insiders own 25.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/27/prudential-financial-inc-grows-position-in-collegium-pharmaceutical-inc-coll.html.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply